Advertisement

Pharmaceutical Chemistry Journal

, Volume 41, Issue 1, pp 50–53 | Cite as

Methods of quality standardization for diumancal parent substance and related medicinal forms

  • A. Z. Abyshev
  • I. K. Zhurkovich
  • E. M. Agaev
  • A. A. Abdulla-zade
  • A. B. Guseinov
Article

Abstract

Methods for the standardization of the parent substance of the original domestic antiischemic drug diumancal and its medicinal forms have been developed. Taking into account the high level of basic requirements on analytical methods and their validation for suitability in the pharmaceutical analysis of medical products, it is suggested to include HPLC, IR, and 13C NMR spectroscopy techniques into the “Identity,” “Extraneous Impurities,” and “Quantitative Determination” articles together with the well-known conventional methods. In order to ensure the reliability and specificity of determination of the content of the parent substance, the State Reference Sample (SRS) of diumancal is created and the retention times of possible impurities in diumancal are established using mixtures of 7-oxy-2-H-1-benzopyran-2-one and 7-(2-bromoethyleneoxy)-2-H-1-benzopyran-2-one. The total content of these impurities must not exceed 0.5 %. Experimental data on the analysis of impurities in diumancal are presented and optimum conditions for determining diumancal in the parent substance and related medicinal forms are established. The rated parameters of the “Identity,” “Extraneous Impurities,” and “Quantitative Determination” articles for these preparations are established, which can be used for both research and the production quality control purposes.

Keywords

Parent Substance Medicinal Form Measuring Flask Asymmetry Coefficient Nujol Mull 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    J. M. Green, A Practical Guide to Analytical Method Validation. Analytical Chemistry News and Features, pp. 305A–309A (1996).Google Scholar
  2. 2.
    British Pharmacopoeia (2001), Vol. 11, Appendix III, pp. A141–A144.Google Scholar
  3. 3.
    C. M. Riley, T. W. Rosanske, Development and Validation of Analytical Methods, Progress in Pharmaceutical and Biomedical Analysis, Elsevier, New York (1996), Vol. 3.Google Scholar
  4. 4.
    S. Burke, LC-GC Europe Online Supplement, Statistics and Data Analysis (2002), pp. 13–18.Google Scholar
  5. 5.
    I. Krul, M. Swartz, Quantitation in Method Validation, LC-GC, 16(12), 1084–1090 (1998).Google Scholar
  6. 6.
    N. A. Epshtein, Khim.-Farm. Zh., 38(4), 40–56 (2004).Google Scholar
  7. 7.
    A. Z. Abyshev, P. P. Denisenko, and M. P. Pukhov, RF Patent No. 1836086 (1992).Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2007

Authors and Affiliations

  • A. Z. Abyshev
    • 1
  • I. K. Zhurkovich
    • 1
  • E. M. Agaev
    • 1
  • A. A. Abdulla-zade
    • 1
  • A. B. Guseinov
    • 1
  1. 1.St. Petersburg Institute of Vaccines and SeraResearch and Production CorporationSt. PetersburgRussia

Personalised recommendations